EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype

Jasmin Hatami, Krishna Das, Leonie Wolf, Andreas Aufschnaiter, Janine Kimpel, Tobias Nolden, Liesa-Marie Schreiber, Brigitte Müllauer, Elke Podgorschek, Theresa Schwaiger, Bart Spiesschaert, Guido Wollmann und 3 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Jasmin Hatami und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interleukin-12, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Christian Doppler Forschungsgesellschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vesicular stomatitis virus (VSV) pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (VSV-GP) represents a potent oncolytic virus (OV). Oncolytic virotherapy is an emerging anticancer approach that uses viruses to eliminate cancer cells by direct cell lysis and induction of an antitumor immune response. Immunomodulatory cargos expressed by OVs hold the potential to further enhance this antitumor immune response.

Methods

To evaluate interleukin-12 (IL-12) as an immunomodulatory cargo encoded by VSV-GP, we used a subcutaneous tumor model by mixing type I interferon (IFN) competent murine lung epithelial cells (TC-1), which are largely resistant to VSV-GP in vivo, with VSV-GP permissive IFN-α receptor knockout TC-1 cells (TC-1 ifnar1 −/ − ).

Results

This mixed model supports prolonged viral replication and subsequent IL-12 production. Oncolytic virotherapy with VSV-GP and VSV-GP-IL12 of parental TC-1 tumors did not lead to tumor control, whereas virus treatment in the TC-1/TC-1 ifnar1 −/− mixed tumors showed prolonged survival. Furthermore, VSV-GP-IL12 was even more effective than VSV-GP treatment. Analysis of CD8+ T cell responses revealed phenotypic differences of activated CD8+ T cells between VSV-GP and VSV-GP-IL-12 treatment, whereby VSV-GP-IL12-induced CD8+T cells displayed a phenotype described for long-lived effector cells (LLEC). Depletion experiments indicated that CD8+ T cells, and not NK cells, were responsible for the improved efficacy observed with VSV-GP-IL12 treatment.

Conclusions

Taken together, we have demonstrated that oncolytic virotherapy using VSV-GP encoding IL-12 induces CD8+ T cell responses characterized by an LLEC phenotype, a cell population that is likely a crucial component of antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesInterleukin-12Oncolytic VirotherapyOncolytic VirusesLymphocytic choriomeningitis virusAnimalsMiceCell Line, TumorHumansPhenotypeVesicular stomatitis Indiana virusFemale

Stichwörter der Autor:innen

AdaptiveCombination therapyImmune modulatoryOncolytic virusT-Lymphocytes

Substanzen

Interleukin-12

Autor:innen und Institutionen

  • Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
  • ViraTherapeutics GmbH, Rum, Tyrol, Austria.
  • Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
  • Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
  • Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria zoltan.banki@i-med.ac.at.

Förderung

  • Christian Doppler Forschungsgesellschaft

Zitieren

APA

Hatami, J., Das, K., Wolf, L., Aufschnaiter, A., Kimpel, J., Nolden, T., Schreiber, L. M., Müllauer, B., Podgorschek, E., Schwaiger, T., Spiesschaert, B., Wollmann, G., Elbers, K., von Laer, D., & Bánki, Z. (2025). Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010675

Vancouver

Hatami J, Das K, Wolf L, Aufschnaiter A, Kimpel J, Nolden T, et al. Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010675

BibTeX
@article{Hatami2025,
  author = {Hatami, Jasmin and Das, Krishna and Wolf, Leonie and Aufschnaiter, Andreas and Kimpel, Janine and Nolden, Tobias and Schreiber, Liesa-Marie and Müllauer, Brigitte and Podgorschek, Elke and Schwaiger, Theresa and Spiesschaert, Bart and Wollmann, Guido and Elbers, Knut and von Laer, Dorothee and Bánki, Zoltán},
  title = {Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010675}
}
Kostenlos starten →